RT Journal Article
T1 Reversing the Tumor Target: Establishment of a Tumor Trap
A1 Najberg, Mathie
A1 Haji Mansor, Muhammad
A1 Boury, Frank
A1 Álvarez Lorenzo, Carmen
A1 Garcion, Emmanuel
K1 Tumor cell migration
K1 Tumor trap
K1 Biomimetic trap
K1 Cancer therapy
K1 Premetastatic niche recruitment
AB Despite the tremendous progress made in the field of cancer therapy in recent years, certain solid tumors still cannot be successfully treated. Alongside classical treatments in the form of chemotherapy and/or radiotherapy, targeted treatments such as immunotherapy that cause fewer side effects emerge as new options in the clinics. However, these alternative treatments may not be useful for treating all types of cancers, especially for killing infiltrative and circulating tumor cells (CTCs). Recent advances pursue the trapping of these cancer cells within a confined area to facilitate their removal for therapeutic and diagnostic purposes. A good understanding of the mechanisms behind tumor cell migration may drive the design of traps that mimic natural tumor niches and guide the movement of the cancer cells. To bring this trapping idea into reality, strong efforts are being made to create structured materials that imitate myelinated fibers, blood vessels, or pre-metastatic niches and incorporate chemical cues such as chemoattractants or adhesive proteins. In this review, the different strategies used (or could be used) to trap tumor cells are described, and relevant examples of their performance are analyzed.
PB Frontiers Media
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21195
UL http://hdl.handle.net/10347/21195
LA eng
NO Najberg, M., Haji Mansor, M., Boury, F., Alvarez-Lorenzo, C., Garcion, E. (2019). Reversing the Tumor Target: Establishment of a Tumor Trap. "Frontiers in Pharmacology", 10:887
NO This work was supported by the “Institut National de la Santé et de la Recherche Médicale” (INSERM), the University of Angers (Angers, France), the MINECO (SAF2017-83118-R), the Agencia Estatal de Investigacion (AEI, Spain), and the Fondo Europeo de Desarollo Regional (FEDER). It is also related to the LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology” as part of the French government “Investissements d’Avenir” program, to the INCa (Institut National du Cancer) MARENGO consortium “MicroRNA agonist and antagonistNanomedicines for GliOblastoma treatment: from molecular programmation to preclinical validation” through the PL-BIO 2014-2020 grant and to the MuMoFRaT project “Multi-scale Modeling & simulation of the response to hypo-Fractionated Radiotherapy or repeated molecular radiation Therapies” supported by “La Région Pays-de-la-Loire” and by theCancéropôle Grand-Ouest (tumor targeting and radiotherapy network). MN was a Ph.D. student involved in the Erasmus Mundus Joint Doctorate program for Nanomedicine andpharmaceutical innovation (EMJD NanoFar) and received a fellowship from “La Région Pays-de-la-Loire.”
DS Minerva
RD 24 abr 2026